Phase II Study of Bevacizumab and Vorinostat for Patients With Recurrent World Health Organization Grade 4 Malignant Glioma

Oncologist - United States
doi 10.1634/theoncologist.2017-0501
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

Phase I Study of Sunitinib and Irinotecan for Patients With Recurrent Malignant Glioma

Journal of Neuro-Oncology
Cancer ResearchOncologyNeurology
2011English

Timing of Surgery and Bevacizumab Therapy in Neurosurgical Patients With Recurrent High Grade Glioma

Journal of Clinical Neuroscience
MedicineSurgeryNeurologyPhysiology
2015English

Temozolomide and Reirradiation in Recurrent Grade II Brain Glioma

World Journal of Oncology
Cancer ResearchOncology
2014English

The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients With High-Grade Glioma

Academic Radiology
Nuclear MedicineRadiologyImaging
2016English

Bevacizumab Monotherapy for Temozolomide-Refractory Malignant Glioma

Japanese Journal of Neurosurgery
SurgeryNeurology
2010English

Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas

2012English

Bevacizumab and Fotemustine for Recurrent Glioblastoma: A Phase II Study of AINO (Italian Association of Neuro-Oncology)

Journal of Neuro-Oncology
Cancer ResearchOncologyNeurology
2013English

A Pilot Study of Peptide Vaccines for VEGF Receptor 1 and 2 in Patients With Recurrent/Progressive High Grade Glioma

Oncotarget
Oncology
2018English

Antiangiogenic Therapy Using Bevacizumab in Recurrent High-Grade Glioma: Impact on Local Control and Patient Survival

Journal of Neurosurgery
SurgeryNeurology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy